An Open Question: Is It Rational to Inhibit the mTor-Dependent Pathway as COVID-19 Therapy?

Front Pharmacol. 2020 May 29:11:856. doi: 10.3389/fphar.2020.00856. eCollection 2020.

¹ Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.
² Department of Science, University of Basilicata, Potenza, Italy.

No abstract available

Keywords: COVID-19; Everolimus; hyper-activation; immune-regulation; mTOR.